Abstract:To report the physical dosimetry study and preliminary results of a prospective study evaluating 3D-printing template assisted with CT-guidance for 125I seed brachytherapy to treat recurrent or metastatic gynecological carcinoma. In this retrospective study, with median follow-up of 10 months for all patients, 95 patients were enrolled and analyzed; inclusion criteria were Karnofsky performance status 60 to 100, expected overall survival >3 months, patients were pathologically or radiologically confirmed to be recurrent or metastatic gynecological carcinoma and the tumors were unresectable due to individual rejection or surgeon consultation. All patients have accepted 3D-printing template assisted with CT-guidance for 125I seed brachytherapy. Kaplan-Meier survival analysis was used to estimate local control (LC), overall survival (OS), and progression-free survival (PFS). We analyzed the confounding factors that affected LC, PFS, and OS by using Cox proportional hazards regression model. Acute and late toxic effects were prospectively assigned by using the Radiation Therapy Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC) criteria. Of 87 patients (median [range] age, 53 [29-92] years; vulvar cancer, 2 [2%]; endometrial cancer, 10 [11%]; cervical cancer, 72 [83%]; ovarian cancer, 3 [3%]), 32 (37%) were alive at last follow-up. 9 (10%) patients adopted secondary RIS implantation on different sites. 75% quantile LC was 16 months (1-year LC, 85%; 95%CI, 77%-93%). Median PFS was 12 months (1-year PFS, 48%; 95%CI, 36%-59%). Median OS was 15 months (1-year OS, 65%; 95%CI, 54%-76%). On multivariate analysis, GTV D100 >60Gy independently correlative for good LC (hazard ratio [HR], 0.139; 95% CI, 0.037-0.527; P=.004), PFS (HR, 0.346; 95% CI, 0.180-0.666; P=.001) and OS (HR, 0.185; 95% CI, 0. 083-0.416; P<.001). Rates of grade 2 acute radiothermitis, vomiting, proctitis and hematuresis were 2 (2%), 1 (1%), 3 (3%) and 2 (2%). Acute grade 3 proctitis occurred in 1 (1%) patient. Late toxic effects were uncommon: 1 (1%) patient developed an hematuresis (grade 2) and 1 (1%) patient developed an rectovaginal fistula. There were no acute or late grade 5 toxic effects. 125I seed brachytherapy to treat recurrent or metastatic gynecologic carcinoma showed promising clinical outcomes and rates of toxic effects. Further optimization of 125I seed brachytherapy is needed in order to improve the accuracy of treatment.

3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes

Application of 3D Printing in Cervical Cancer Brachytherapy

3D printing in brachytherapy: A systematic review of gynecological applications

Dosimetric parameters and safety analysis of 3D-printing non-coplanar template-assisted interstitial brachytherapy for non-centrally recurrent cervical cancer

3D-printed individual template brachytherapy for the treatment of intractable central pelvic recurrent cervical cancer: A single institution experience

Comparison of 3D-printed multichannel non-co-planar vaginal applicators and single-channel vaginal applicators for brachytherapy with positive or close surgical margins in cervical cancer

3D Printing Individual Applicator Used for Interstitial Brachytherapy in Recurrent Cervical Cancer

Clinical Research of 3d Printing Template-assisted 125 I Radioactive Seed Interstitial Brachytherapy for Malignant Tumors

The Clinical Results and Physical Dosimetry Study of 3D-Printing Template Assisted with CT-Guidance for 125I Seed Brachytherapy in Recurrent or Metastatic Gynecologic Carcinoma

Nursing Report of One Case of Recurrent Cervical Cancer Patient Treated by After-Loading Therapy with Interstitial Brachytherapy Assisted by 3D Printing Source Device

The Application and Comparation of Transcutaneous and Transmucosal 3D Printing Individual Templates Guiding Brachytherapy in Oral and Pharynx Area

PHSOR02 Presentation Time: 10:05 AM

The Use of 3D Printing Technology in Gynaecological Brachytherapy—A Narrative Review

B-ultrasound or CT-guided 3D-printing individualized non-coplanar template brachytherapy for the treatment of locally uncontrolled recurrent head and neck squamous cell carcinoma

Dosimetric Study of 3D-Printing Coplanar Template Combined with CT-guided 125I Seed Implantation for Treating Non-Small Cell Lung Cancer

Evaluation and improvement of the safety of 3D-printed template assisted intracavitary/interstitial brachytherapy for cervical cancer using repeat FMEA

Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort

The Dosimetry Evaluation of 3D Printing Non-Coplanar Template-Assisted CT-guided 125I Seed Stereotactic Ablation Brachytherapy for Pelvic Recurrent Rectal Cancer after External Beam Radiotherapy.

Clinical Application of 3D-Printing Individual Template Assisted HDR 192 Ir Interstitial Brachytherapy for Central Recurrence of GYN after Pelvic EBRT

Accuracy Evaluation of a 3D-Printed Individual Template for Needle Guidance in Head and Neck Brachytherapy

Individual curved‐needle interstitial template created using three‐dimensional printing for brachytherapy for distal parauterine tumor recurrence